iRhythm Technologies Unveils New Data Showing Consistent Zio LTCM Performance in Asian Patients

Reuters11-21

iRhythm Technologies Unveils New Data Showing Consistent Zio LTCM Performance in Asian Patients

iRhythm Technologies Inc. has announced new data presented at the 18th Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JHRS) 2025 Joint Scientific Session in Yokohama, Japan, held November 12-15. The study, led by Dr. Hiro Kawata, compared device compliance, performance, arrhythmia detection, and repeat-testing rates between Asian and non-Asian populations in a large cohort of 408,470 U.S. patients monitored with iRhythm's Zio long-term continuous ECG monitoring (LTCM) service from 2018 to 2022. The results demonstrated that median wear and analyzable time among Asian patients were comparable to those of non-Asian patients, and the findings were consistent with previously published studies. iRhythm is also collaborating with investigators in Japan to further expand evidence across local patient populations and clinical settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRhythm Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9580184-en) on November 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585143281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585143281","market":"fut","top_or_hot":-1,"title":"iRhythm Technologies Unveils New Data Showing Consistent Zio LTCM Performance in Asian Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      iRhythm Technologies Unveils New Data Showing Consistent Zio LTCM Performance in Asian Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        iRhythm Technologies Inc. has announced new data presented at the 18th Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JHRS) 2025 Joint Scientific Session in Yokohama, Japan, held November 12-15. The study, led by Dr. Hiro Kawata, compared device compliance, performance, arrhythmia detection, and repeat-testing rates between Asian and non-Asian populations in a large cohort of 408,470 U.S. patients monitored with iRhythm's Zio long-term continuous ECG monitoring (LTCM) service from 2018 to 2022. The results demonstrated that median wear and analyzable time among Asian patients were comparable to those of non-Asian patients, and the findings were consistent with previously published studies. iRhythm is also collaborating with investigators in Japan to further expand evidence across local patient populations and clinical settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRhythm Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9580184-en) on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iRhythm Technologies Unveils New Data Showing Consistent Zio LTCM Performance in Asian Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niRhythm Technologies Unveils New Data Showing Consistent Zio LTCM Performance in Asian Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-21 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      iRhythm Technologies Unveils New Data Showing Consistent Zio LTCM Performance in Asian Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        iRhythm Technologies Inc. has announced new data presented at the 18th Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JHRS) 2025 Joint Scientific Session in Yokohama, Japan, held November 12-15. The study, led by Dr. Hiro Kawata, compared device compliance, performance, arrhythmia detection, and repeat-testing rates between Asian and non-Asian populations in a large cohort of 408,470 U.S. patients monitored with iRhythm's Zio long-term continuous ECG monitoring (LTCM) service from 2018 to 2022. The results demonstrated that median wear and analyzable time among Asian patients were comparable to those of non-Asian patients, and the findings were consistent with previously published studies. iRhythm is also collaborating with investigators in Japan to further expand evidence across local patient populations and clinical settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRhythm Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9580184-en) on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL54my3x:1","article_id":"2585143281","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585143281","pubTimestamp":1763730615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"iRhythm Technologies Inc. has announced new data presented at the 18th Asia Pacific Heart Rhythm Society  and Japanese Heart Rhythm Society  2025 Joint Scientific Session in Yokohama, Japan, held November 12-15. The study, led by Dr. Hiro Kawata, compared device compliance, performance, arrhythmia detection, and repeat-testing rates between Asian and non-Asian populations in a large cohort of 408,470 U.S. patients monitored with iRhythm's Zio long-term continuous ECG monitoring  service from 2018 to 2022. The results demonstrated that median wear and analyzable time among Asian patients were comparable to those of non-Asian patients, and the findings were consistent with previously published studies. iRhythm is also collaborating with investigators in Japan to further expand evidence across local patient populations and clinical settings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4563":"昨日强势股","NDAQ":"纳斯达克OMX交易所","BK4082":"医疗保健设备","IRTC":"Irhythm Technologies Inc."},"translate_title":"iRhythm Technologies公布新数据显示Zio LTCM在亚洲患者中的表现一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRTC":0.9,"NDAQ":0.9},"content_text":"iRhythm Technologies Unveils New Data Showing Consistent Zio LTCM Performance in Asian Patients\n    \n\n        iRhythm Technologies Inc. has announced new data presented at the 18th Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JHRS) 2025 Joint Scientific Session in Yokohama, Japan, held November 12-15. The study, led by Dr. Hiro Kawata, compared device compliance, performance, arrhythmia detection, and repeat-testing rates between Asian and non-Asian populations in a large cohort of 408,470 U.S. patients monitored with iRhythm's Zio long-term continuous ECG monitoring (LTCM) service from 2018 to 2022. The results demonstrated that median wear and analyzable time among Asian patients were comparable to those of non-Asian patients, and the findings were consistent with previously published studies. iRhythm is also collaborating with investigators in Japan to further expand evidence across local patient populations and clinical settings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRhythm Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9580184-en) on November 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585143281","isCrawlerRequest":true}